Long-term virologic and immunologic responses in human immunodeficiency virus type 1-infected children treated with indinavir, zidovudine, and lamivudine

J Infect Dis. 2001 Apr 1;183(7):1116-20. doi: 10.1086/319274. Epub 2001 Mar 1.

Abstract

Virologic and immunologic responses were examined for 33 human immunodeficiency virus (HIV)-infected children who participated for > or = 96 weeks in a phase 1/2 protocol of 16 weeks of indinavir monotherapy, followed by the addition of zidovudine and lamivudine. At week 96, a median increase of 199 CD4+ T cells/microL and a median decrease of 0.74 log(10) HIV RNA copies/mL were observed. The relationship between control of viral replication and CD4) T cell count was examined. Patients were categorized into 3 response groups on the basis of duration and extent of control of viral replication. Of 21 children with a transient decrease in virus load of > or = 0.7 log(10) HIV RNA copies/mL from baseline, 7 experienced sustained increases in CD4+, CD4+ CD45RA+, and CD4+ CD45RO+ T cell counts. CD4+ CD45RA+ (naive) T cells were the major contributor to CD4+ T cell expansion. Continued long-term immunologic benefit may be experienced by a subset of children, despite only transient virologic suppression.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adolescent
  • Anti-HIV Agents / therapeutic use*
  • CD4 Antigens / analysis
  • CD4 Lymphocyte Count
  • Child
  • Child, Preschool
  • Drug Therapy, Combination
  • Female
  • Follow-Up Studies
  • HIV Infections / drug therapy*
  • HIV Infections / immunology
  • HIV Infections / virology
  • HIV Protease Inhibitors / therapeutic use*
  • HIV* / isolation & purification
  • Humans
  • Indinavir / therapeutic use*
  • Lamivudine / therapeutic use*
  • Leukocyte Common Antigens / analysis
  • Male
  • Protein Tyrosine Phosphatase, Non-Receptor Type 1
  • RNA, Viral / analysis
  • Viral Load
  • Zidovudine / therapeutic use*

Substances

  • Anti-HIV Agents
  • CD4 Antigens
  • HIV Protease Inhibitors
  • RNA, Viral
  • Lamivudine
  • Zidovudine
  • Indinavir
  • Leukocyte Common Antigens
  • Protein Tyrosine Phosphatase, Non-Receptor Type 1